Immunocore CEO: 3rd Big Pharma Eying Unique Cancer Targeting Tech

Update: 2013-07-16

Description

Immunocore is looking for more licensees for its cancer targeting technology following recent discovery and development deals with GSK and Genentech.

Comments

In Channel

Podcast: The British start-up taking psychedelic therapy mainstream

2023-10-1628:03

What kind of consistency can industry expect from the FDA post pandemic?

2021-07-2215:05

Chicago emerging as a life science and biopharma hub

2021-05-1714:56

Will Biden backed bills boost biosimilars uptake in the US?

2021-05-0708:48

Bioproduction bottlenecks increasing due to staff shortages, says report

2017-08-1504:01

'The sexiness of the ADC world' - CMOs talk antibody-drug hybrids at CPhI

2013-10-3005:42

Better single-use cross flow techs still needed says GE Healthcare

2013-10-1503:05

Immunocore CEO: 3rd Big Pharma Eying Unique Cancer Targeting Tech

2013-07-1605:10

Customers to Save up to 65% as ASI and Chromatan Pen Single-Use Deal

2013-04-2905:08

ATMI: Single Use Bioreactors on the Up, but US Tails Europe

2013-02-2004:43

The single-use age has dawned, says ThermoFisher

2012-05-2005:16

European CMO market will double in just 6 years, says Frost & Sullivan

2012-03-1505:49

Acuros in talks with Big Pharma over water-powered delivery pump

2012-03-1305:54

Unilife launches Autoinfuser range publically

2012-02-2304:25

EMD Millipore talks integration: of processes; and with owner Merck KGaA

2011-04-0504:04

OctoPlus, Glycotope, Merck KGaA and SCM Pharma on BioPh 2009

2009-10-2904:15

Gene therapy to drive viral and biologics market, says SAFC

2009-10-1306:14

BIO 2009: snapshot of an evolving biotech industry

2009-05-2101:59

00:00

#box-pro-ellipsis-176293106366010{-webkit-line-clamp:2;}Immunocore CEO: 3rd Big Pharma Eying Unique Cancer Targeting Tech